TritonPoint Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

TritonPoint Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$273K	Buy	612 +95	+18%	+$44.3K	0.03%	228
2025 Q4	$234K	Sell	517 -31	-6%	-$13.4K	0.02%	245
2025 Q3	$215K	Sell	548 -53	-9%	-$22.1K	0.02%	334
2025 Q2	$268K	Sell	601 -3	-0.5%	-$1.38K	0.02%	293
2025 Q1	$293K	Buy	604 +83	+16%	+$38.7K	0.03%	280
2024 Q4	$210K	Sell	521 -7	-1%	-$3.25K	0.02%	323
2024 Q3	$244K	Buy	528 +35	+7%	+$16.8K	0.02%	301
2024 Q2	$231K	Buy	+493	New	+$214K	0.02%	295

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

TritonPoint Wealth's VRTX Position: Q1 2026 in Review

TritonPoint Wealth increased its Vertex Pharmaceuticals (VRTX) stake by 18% in Q1 2026, buying an estimated $44.3K and bringing the position to 612 shares worth $273K. The position accounts for 0.03% of the portfolio, ranked #228.

TritonPoint Wealth first reported a position in VRTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $293K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

TritonPoint Wealth held 612 shares of Vertex Pharmaceuticals worth $273K as of Q1 2026.
TritonPoint Wealth bought 95 Vertex Pharmaceuticals shares in Q1 2026, an estimated $44.3K.
Vertex Pharmaceuticals made up 0.03% of TritonPoint Wealth's portfolio in Q1 2026, its #228 holding.
TritonPoint Wealth first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
TritonPoint Wealth's Vertex Pharmaceuticals position peaked at $293K in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on TritonPoint Wealth's 13F filing for Q1 2026, filed 21 Apr 2026.